RANDOMIZED DOUBLE-BLIND TRIAL OF TERODILINE IN THE TREATMENT OF URGE INCONTINENCE IN WOMEN

Objective: To evaluate the effects of terodiline in women with urge in continence. Methods: After a 2-week run-in period, 93 women with urina ry frequency and urge incontinence were randomized to either placebo o r terodiline, 25 mg twice daily, in a double-blind study for 4 weeks. Symptoms were evaluated using daily frequency-volume charts to record voiding frequency, number of incontinent episodes, absorbent pad use, and quality of life. Results: The terodiline group showed a 70% decrea se in the mean (+/- standard deviation) number of incontinent episodes per week (15.8 +/- 24, decreasing to 4.9 +/- 11.9; P < .01), which pe rsisted throughout the study period. The placebo group achieved a 9% r eduction in the mean number of incontinent episodes (13.0 +/- 11.3, de creasing to 11.9 +/- 16; P <.05) only in the final week of treatment S ide effects, especially anticholinergic side effects, were more common in the terodiline group, but resulted in only one dropout. Both the t reated and placebo groups improved in daytime frequency and quality-of -life indices. Conclusion: Terodiline is well tolerated and effective in reducing urge incontinent episodes in women.